Detail akcie CELON PHARMA online

Business Summary: Celon Pharma SA is a Poland-based company primarily engaged in the pharmaceuticals manufacture. The Company focuses on research, development and production of generic drugs for cancer, neurological diseases, diabetes and other metabolic disorders treatment, among others. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir and Valzek, as well as inhalation powder, such as Salmex. The Company's research center develops pharmaceuticals within a number of therapeutic areas, including oncology, neurology, as well as inflammatory and metabolic diseases. The Company is a subsidiary of Glatton sp z o o.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Celon Pharma SA revenues decreased 4% to PLN207.2M. Net loss increased 22% to PLN34.4M. Revenues reflect Innovative-Poland segment decrease of 45% to PLN27.4M, Generic Medicines-Foreign segment decrease of 30% to PLN41.6M. Higher net loss reflects Innovative segment income decrease of 30% to PLN18.7M, Generic Medicines segment loss increase of 3% to PLN55.5M.